Mariana Paes Dias

Mariana Paes Dias

Auto-generated profile, based on publicly available information

Mariana Paes Dias

Division of Molecular Pathology, the Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2021 in Nature Reviews Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MDMariana Paes Dias
Mariana Paes Dias
SMSarah C. Moser
Sarah C. Moser
SGShridar Ganesan
Shridar Ganesan
JJJos Jonkers
Jos Jonkers

22 September 2021 in Molecular Cell
Verified
Journal Article
Closed access
MDMariana Paes Dias
Mariana Paes Dias
VTVivek Tripathi
Vivek Tripathi
IHIngrid van der Heijden
Ingrid van der Heijden
KCKe Cong
Ke Cong
EMEleni-Maria Manolika
Eleni-Maria Manolika
JJJos Jonkers
Jos Jonkers

7 May 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CLCalvin Shun Yu Lo
Calvin Shun Yu Lo
MTMarvin van Toorn
Marvin van Toorn
VGVincent Gaggioli
Vincent Gaggioli
MDMariana Paes Dias
Mariana Paes Dias
YZYifan Zhu
Yifan Zhu
NTNitika Taneja
Nitika Taneja
The interplay of SMARCAD1-mediated active fork and BRCA1-mediated stalled fork stability pathways maintains genome integrity.

2 November 2021 in Molecular & Cellular Oncology
Verified
Journal Article
Closed access
MDMariana Paes Dias
Mariana Paes Dias
JJJos Jonkers
Jos Jonkers
Tumors with loss of breast cancer type 1 susceptibility protein (BRCA1) are homologous recombination (HR) deficient and hypersensitive to poly(ADP-ribose) polymerase inhibitors (PARPi). However, these tumors may restore HR and acquire PARPi resistance via loss of end-protection of DNA double-strand breaks. We found that loss of nuclear DNA ligase III resensitizes HR-restored BRCA1-deficient cells to PARPi by exposing post-replicative single-stranded DNA (ssDNA) gaps. Our work, and that of others, identifies ssDNA gaps as a key determinant of PARPi response.

1 December 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
Mafalda OliveiraMafalda Oliveira
Mafalda Oliveira
ECEva Maria Ciruelos
Eva Maria Ciruelos
GVGuillermo Villacampa
Guillermo Villacampa
SMSerafin Morales
Serafin Morales
JSJavier Salvador-Bofill
Javier Salvador-Bofill
CMCristina Saura Manich
Cristina Saura Manich
Purpose: The aim of this study was to evaluate the safety and feasibility of ipatasertib combined with trastuzumab and pertuzumab (HP) as maintenance therapy after first-line treatment in patients with HER2-positive metastatic breast cancer harboring PIK3CA mutations (PIK3CAmut). Patients and Methods: This prospective, multicenter, single-arm, phase Ib study evaluated the safety and preliminary efficacy of ipatasertib, an AKT inhibitor, combined with HP, with or without endocrine therapy as maintainance therapy, in patients with unresectable locally advanced or metastatic PIK3CAmut, HER2-positive breast cancer following first-line induction chemotherapy and HP. Results: Seventeen patients were enrolled, with a median follow-up of 27.7 months. During the dose-selection phase, ipatasertib at 400 mg daily (21 days on and 7 days off) with standard HP was established as the recommended phase II dosage. This decision was based on the absence of dose-limiting toxicities in the first six patients treated at this dosage during the initial 28-day cycle, which constituted the primary endpoint. Grade 3 treatment-related adverse events (TRAE) occurred in seven patients (41.2%), most commonly diarrhea and nausea. Two (11.8%) reported four serious TRAE (diarrhea, vomiting, ischemic stroke, and pneumonitis, one case each) related to ipatasertib, from which they recovered. The confirmed overall response rate was 31.1% [95% confidence interval (CI), 12.1%–58.5%], clinical benefit rate 84.6% (95% CI, 53.7%–97.3%), and median progression-free survival 16.4 months (95% CI, 9.4–NR); 47.3% of patients were progression free at 18 months. Conclusions: These results support ipatasertib plus HP as a safe and promising maintenance strategy for HER2-positive breast tumors harboring PIK3CAmut.

26 January 2022 in STAR Protocols
Verified
Journal Article
Open access
MDMariana Paes Dias
Mariana Paes Dias
SRSven Rottenberg
Sven Rottenberg
JJJos Jonkers
Jos Jonkers
We have previously developed 3D tumoroids derived from genetically engineered mouse models (GEMMs) of BRCA1/2-deficient breast cancer. Here, we describe how to genetically modify tumoroids, use them for functional genetic dropout screens, and carry out orthotopic transplantation of modified tumoroids. The purpose of this protocol is to screen for therapeutic targets and allow rapid and straightforward in vivo validation of the candidate targets.